FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and Human Services announced that the ...

A US pharmaceutical giant could face suspension in the UK for engaging in “unacceptable practices” Read Full Article at ...

If found to be lacking adequate compliance systems, Moderna could ultimately be suspended or expelled from the Association of ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Moderna (NasdaqGS:MRNA) experienced a 10% share price increase, coinciding with broader market gains but slightly below the Nasdaq Composite's 5% rise. Despite the market being uplifted by strong ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BofA lowered the firm’s price target on Moderna (MRNA) to $26 from $32 and keeps an Underperform rating on the shares. For 2025, the firm’s ...